The "Anti-obesity Drugs Market by Type (class III anti-obesity drugs, class II anti-obesity drugs, and class I anti-obesity drugs) and Geography (North America, Europe, Asia, and ROW) - Forecast and Analysis 2021-2025" report has been added to Technavio's offering. The potential growth difference for the anti-obesity drugs market between 2020 and 2025 is USD 454.51 mn.
Key Market Challenge
The availability of anti-obesity devices will challenge the global anti-obesity drugs market. Various physical activities and weight loss supplements are considered preventive measures for obesity. Apart from this, there are obesity treatment devices such as gastric band and electrical stimulation system. These devices are highly preferred owing to their fast results. Thus, many obese people prefer to undergo these treatments instead of taking drugs. Therefore, the growing adoption of anti-obesity devices is a major challenge for the growth of the global anti-obesity drug market.
Market Segmentation
The anti-obesity drugs market report is segmented by type (class III anti-obesity drugs, class II anti-obesity drugs, and class I anti-obesity drugs) and geography (North America, Europe, Asia, and ROW).
By type, the class III anti-obesity drugs segment will have significant market share growth during the forecast period. Most of the drugs offered in the market are targeted at patients who are categorized under class III. Moreover, the rise in R&D by manufacturers for new anti-obesity drugs may boost the growth of the global class III anti-obesity drugs market during the forecast period.
By geography, North America will be the leading region with 71% of the market's growth during the forecast period. The US and Canada are the key countries for the anti-obesity drugs market in the region. The presence of a large obese population will drive the anti-obesity drugs market growth in North America during the forecast period. Moreover, market growth in this region will be slower than the growth of the market in other regions.
View our sample report for additional insights into the contribution of all the segments, and regional opportunities in the report.
Some Companies Mentioned
- Bausch Health Companies Inc.
- Currax Pharmaceuticals LLC
- F. Hoffmann-La Roche Ltd.
- Gelesis Inc.
- GlaxoSmithKline Plc
- Novo Nordisk AS
- RECORDATI S.p.A.
- Rhythm Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- VIVUS Inc.
- To gain access to more vendor profiles with their key offerings available with Technavio, Click Here
Related Reports:
Diuretic Drugs Market by Product Type and Geography - Forecast and Analysis 2022-2026
Uveitis Drugs Market by Product and Geography - Forecast and Analysis 2022-2026
Anti-obesity Drugs Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.32% |
Market growth 2021-2025 |
USD 454.51 million |
Market structure |
Fragmented |
YoY growth (%) |
6.22 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 71% |
Key consumer countries |
US, Germany, UK, Canada, and China |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Bausch Health Companies Inc., Currax Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., Gelesis Inc., GlaxoSmithKline Plc, Novo Nordisk AS, RECORDATI S.p.A., Rhythm Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and VIVUS Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Key Topics Covered:
1 Executive Summary
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 01: Parent market
- 2.2 Market characteristics
- Exhibit 02: Market characteristics
- 2.3 Value chain analysis
- Exhibit 03: Exhibit 10: Pharmaceuticals – Value chain analysis
3 Market Sizing
- 3.1 Market definition
- Exhibit 04: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 05: Market segments
- 3.4 Market outlook: Forecast for 2020 - 2025
- Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
- Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)
4 Five Forces Analysis
- 4.1 Five Forces Summary
- Exhibit 08: Five forces analysis 2020 & 2025
- 4.2 Bargaining power of buyers
- Exhibit 09: Bargaining power of buyers
- 4.3 Bargaining power of suppliers
- Exhibit 10: Bargaining power of suppliers
- 4.4 Threat of new entrants
- Exhibit 11: Threat of new entrants
- 4.5 Threat of substitutes
- Exhibit 12: Threat of substitutes
- 4.6 Threat of rivalry
- Exhibit 13: Threat of rivalry
- 4.7 Market condition
- Exhibit 14: Market condition - Five forces 2020
5 Market Segmentation by Type
- 5.3 Class III anti-obesity drugs - Market size and forecast 2020-2025
- Exhibit 17: Class III anti-obesity drugs - Market size and forecast 2020-2025 ($ million)
- Exhibit 18: Class III anti-obesity drugs - Year-over-year growth 2020-2025 (%)
- 5.4 Class II anti-obesity drugs - Market size and forecast 2020-2025
- Exhibit 19: Class II anti-obesity drugs - Market size and forecast 2020-2025 ($ million)
- Exhibit 20: Class II anti-obesity drugs - Year-over-year growth 2020-2025 (%)
- 5.5 Class I anti-obesity drugs - Market size and forecast 2020-2025
- Exhibit 21: Class I anti-obesity drugs - Market size and forecast 2020-2025 ($ million)
- Exhibit 22: Class I anti-obesity drugs - Year-over-year growth 2020-2025 (%)
- 5.6 Market opportunity by Type
- Exhibit 23: Market opportunity by Type
6 Market segmentation by Mechanism of Action
- 6.2 Centrally acting anti-obesity drugs
- 6.3 Peripherally acting anti-obesity drugs
- 6.4 Other anti-obesity drugs
7 Customer landscape
8 Geographic Landscape
- 8.1 Geographic segmentation
- 8.2 Geographic comparison
- 8.3 North America - Market size and forecast 2020-2025
- 8.4 Europe - Market size and forecast 2020-2025
- 8.5 Asia - Market size and forecast 2020-2025
- 8.6 ROW - Market size and forecast 2020-2025
- 8.7 Key leading countries
- 8.8 Market opportunity by geography
9 Drivers, Challenges, and Trends
10 Vendor Landscape
- 10.2 Landscape disruption
11 Vendor Analysis
- 11.2 Market positioning of vendors
- 11.3 Bausch Health Companies Inc.
- 11.4 Currax Pharmaceuticals LLC
- 11.5 F. Hoffmann-La Roche Ltd.
- 11.10 Rhythm Pharmaceuticals, Inc.
- 11.11 Teva Pharmaceutical Industries Ltd.
12 Appendix
- 12.2 Currency conversion rates for US$
- 12.3 Research methodology
- 12.4 List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article